Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2015/V12/I3/186

[1] 李世云, 李勤, 甘莉, 等. 甘精胰岛素治疗重组人胰岛素及其类似物过敏二例[J].中国全科医学, 2008, 11(6A): 9987-1000.
[2] 陈铮.警惕胰岛素过敏引发的低血糖[N].中国医药报，2010-06-29- B04版.
[3] 李乃适. 胰岛素过敏的诊断与处理对策[J]. 中华临床免疫和变态反应杂志, 2012, 6(3): 163-167.
[4] 冯文焕, 胡云, 王维敏, 等. 胰岛素吸收不良误诊为胰岛素过敏一例[J]. 新医学, 2011, 42(8): 557-558.
[5] Malaise J, Leonet J, Goffin E, et a1. Pancreas transplantation for treatment of generalized allergy to human insulin in type 1 diabetes[J]. Transplant Proc, 2005, 37(6): 2839.
[6] Cobb CA III, Fung D L. Shock due to protamine hypersensitivity[J].Surg Neurol, 1982, 17(4): 245-246.
[7] Moorthy S S, Pond W, Rowland R G. Severe circulatory shock following protamine (an anaphylactic reaction) [J].Anesth Analg, 1980, 59(1): 77-78.
[8] Vincent G M, Janowski M, Menlove R. Protamine allergy reactions during cardiac catheterization and cardiac surgery: risk in patients taking protamine-insulin preparations[J].Cathet Cardiovasc Diagn, 1991,23(3): 164-168.
[9] Wang C, Ding Z Y, Shu S Q, et al. Severe insulin allergy after percutaneous transluminal coronary angioplasty[J]. Clin Ther, 2009，31(3): 569-574.
[10] 马满玲, 郭美华, 杨丽杰,等. 242 例胰岛素致过敏反应文献分析[J]. 中国药物警戒, 2013, 10(3): 172-175.
[11] 欧阳晓俊, 卞茸文, 顾刘宝, 等.外源性人胰岛素致自身免疫性低血糖一例[J].中华内科杂志, 2008, 47(11): 954-955.
[12] 高莹, 杨建梅, 高燕明, 等. 胰岛素变态反应与低血糖[J].中华糖尿病杂志, 2005, 13(2): 145-146.
[13] Durand-Gonzalez K N, Guillausseau N, Pecquet C, et al. Glargine insulin is not an alternative in insulin allergy[J]. Diabetes Care, 2003, 26(7):2216.
[14] Naoki H, Akira S. Treatment with insulin glargine causes anti-insulin antibody production more frequently than other insulin analogs in patients with diabetes mellitus[J]. Endocr Rev, 2013,34（SAT）：794.

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics